NCT06149247View on ClinicalTrials.gov

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

June 27, 2024

Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
DRUG

Hypericin

HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.

DRUG

Mechlorethamine Topical Gel

Valchlor is an FDA-approved drug for the treatment of CTCL.

Trial Locations (1)

14450

Rochester Skin Lymphoma Medical Group, Fairport

Sponsors

Lead Sponsor

Soligenix
All Listed Sponsors
lead

Soligenix

INDUSTRY